These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 35149851)

  • 1. Bendamustine-EAM versus R-BEAM after high-dose cytarabine-based induction in newly diagnosed patients with mantle cell lymphoma, a LYSA retrospective study.
    Costes-Tertrais D; Hueso T; Gastinne T; Thieblemont C; Oberic L; Bouabdallah K; Garciaz S; Tchernonog E; Dartigeas C; Ribrag V; Fogarty P; Casasnovas RO; Houot R; Delette C; Malak S; Fornecker LM; Gressin R; Damaj G; Le Gouill S
    Bone Marrow Transplant; 2022 Apr; 57(4):627-632. PubMed ID: 35149851
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bendamustine-EAM versus BEAM regimen in patients with mantle cell lymphoma undergoing autologous stem cell transplantation in the frontline setting: a multicenter retrospective study from Lymphoma Study Association (LYSA) centers.
    Hueso T; Gastinne T; Garciaz S; Tchernonog E; Delette C; Casasnovas RO; Durot E; Houot R; Tessoulin B; Tournilhac O; Malak S; Gyan E; Fornecker LM; Abraham J; Delapierre B; Peyrade F; Lemal R; Gressin R; Chantepie S; Borel C; Morello R; Bouabdallah K; Ibrahim A; Bouabdallah R; Le Gouill S; Damaj G
    Bone Marrow Transplant; 2020 Jun; 55(6):1076-1084. PubMed ID: 31953532
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BeEAM (Bendamustine, Etoposide, Cytarabine, Melphalan) Versus BEAM (Carmustine, Etoposide, Cytarabine, Melphalan) as Conditioning Regimen Before Autologous Haematopoietic Cell Transplantation: A Systematic Review and Meta-Analysis.
    Wu R; Ma L
    Cell Transplant; 2023; 32():9636897231179364. PubMed ID: 37350429
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and safety outcomes of BeEAM (Bendamustine, Etoposide, Cytarabine, Melphalan) versus CEM (Carboplatin, Etoposide, Melphalan) in lymphoma patients as a conditioning regimen before autologous hematopoietic cell transplantation.
    Eltelbanei MA; El-Bassiouny NA; Abdalla MS; Khalaf M; Werida RH
    BMC Cancer; 2024 Aug; 24(1):1002. PubMed ID: 39134959
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A retrospective, matched paired analysis comparing bendamustine containing BeEAM versus BEAM conditioning regimen: results from a single center experience.
    Saleh K; Danu A; Koscielny S; Legoupil C; Pilorge S; Castilla-Llorente C; Ghez D; Lazarovici J; Michot JM; Khalife-Saleh N; Lapierre V; Alenxandrova K; Arfi-Rouche J; Bourhis JH; Ribrag V
    Leuk Lymphoma; 2018 Nov; 59(11):2580-2587. PubMed ID: 29164977
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single-center retrospective study assessing the efficacy and safety of BeEAM (bendamustine, etoposide, cytarabine, melphalan) as conditioning regimen for autologous hematopoietic stem cell transplantation.
    Plante MÉ; Feng X; Boudreault JS
    Leuk Lymphoma; 2023; 64(7):1234-1242. PubMed ID: 37154396
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-Dose Bendamustine, Etoposide, Cytarabine, and Melphalan (BeEAM) Conditioning Before Autologous Transplantation for Patients With Multiple Myeloma.
    Solomon SR; Brown S; Shegda N; Jackson KC; Zhang X; Bashey A; Holland HK; Morris LE; Solh M
    Transplant Cell Ther; 2022 Aug; 28(8):486.e1-486.e7. PubMed ID: 35598842
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic differences between carmustine, etoposide, cytarabine and melphalan (BEAM) and carmustine, etoposide, cytarabine, melphalan and fludarabine (BEAMF) regimens before autologous stem cell transplantation plus chimeric antigen receptor T therapy in patients with refractory/relapsed B-cell non-Hodgkin-lymphoma.
    Xin X; Lin L; Yang Y; Wang N; Wang J; Xu J; Wei J; Huang L; Zheng M; Xiao Y; Meng F; Cao Y; Zhu X; Zhang Y
    Cytotherapy; 2024 May; 26(5):456-465. PubMed ID: 38385909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Total Body Irradiation Is Safe and Similarly Effective as Chemotherapy-Only Conditioning in Autologous Stem Cell Transplantation for Mantle Cell Lymphoma.
    Tseng YD; Stevenson PA; Cassaday RD; Cowan A; Till BG; Shadman M; Graf SA; Ermoian R; Smith SD; Holmberg LA; Press OW; Gopal AK
    Biol Blood Marrow Transplant; 2018 Feb; 24(2):282-287. PubMed ID: 29061536
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BeEAM conditioning regimen is a safe, efficacious and economical alternative to BEAM chemotherapy.
    Hahn L; Lim H; Dusyk T; Sabry W; Elemary M; Stakiw J; Danyluk P; Bosch M
    Sci Rep; 2021 Jul; 11(1):14071. PubMed ID: 34234243
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-dose Bendamustine-EAM followed by autologous stem cell rescue results in long-term remission rates in lymphoma patients, without renal toxicity.
    Noesslinger T; Panny M; Simanek R; Moestl M; Boehm A; Menschel E; Koller E; Keil F
    Eur J Haematol; 2018 Sep; 101(3):326-331. PubMed ID: 29799642
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparable safety profile of BeEAM (bendamustine, etoposide, cytarabine, melphalan) and BEAM (carmustine, etoposide, cytarabine, melphalan) as conditioning before autologous haematopoietic cell transplantation.
    Frankiewicz A; Saduś-Wojciechowska M; Najda J; Czerw T; Mendrek W; Sobczyk-Kruszelnicka M; Soska K; Ociepa M; Hołowiecki J; Giebel S
    Contemp Oncol (Pozn); 2018; 22(2):113-117. PubMed ID: 30150889
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BeEAM vs. BEAM: evaluating conditioning regimens for autologous stem cell transplantation in patients with relapsed or refractory DLBCL.
    Wang R; Shangguan X; Zhu Z; Cong D; Bai Y; Zhang W
    Ann Hematol; 2024 Jul; 103(7):2455-2462. PubMed ID: 38809456
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bendamustine or high-dose cytarabine-based induction with rituximab in transplant-eligible mantle cell lymphoma.
    Villa D; Hoster E; Hermine O; Klapper W; Szymczyk M; Bosly A; Unterhalt M; Rimsza LM; Ramsower CA; Freeman CL; Scott DW; Gerrie AS; Savage KJ; Sehn LH; Dreyling M
    Blood Adv; 2022 Sep; 6(18):5285-5294. PubMed ID: 35439293
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bortezomib maintenance after R-CHOP, cytarabine and autologous stem cell transplantation in newly diagnosed patients with mantle cell lymphoma, results of a randomised phase II HOVON trial.
    Doorduijn JK; Zijlstra JM; Lugtenburg PJ; Kersten MJ; Böhmer LH; Minnema MC; MacKenzie MA; van Marwijk Kooij R; de Jongh E; Snijders TJF; de Weerdt O; van Gelder M; Hoogendoorn M; Leys RBL; Kibbelaar RE; de Jong D; Chitu DA; Van't Veer MB; Kluin-Nelemans HC
    Br J Haematol; 2020 Aug; 190(3):385-393. PubMed ID: 32150297
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A multicenter retrospective comparison of induction chemoimmunotherapy regimens on outcomes in transplant-eligible patients with previously untreated mantle cell lymphoma.
    Ng ZY; Bishton M; Ritchie D; Campbell R; Gilbertson M; Hill K; Ratnasingam S; Schwarer A; Manos K; Shorten S; Ng M; Nelson N; Xin L; De Mel Widanalage S; Sunny T; Purtill D; Poon M; Johnston A; Cochrane T; Lee HP; Hapgood G; Tam C; Opat S; Hawkes E; Seymour J; Cheah CY
    Hematol Oncol; 2019 Aug; 37(3):253-260. PubMed ID: 30983008
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Conlon KC; Sportes C; Brechbiel MW; Fowler DH; Gress R; Miljkovic MD; Chen CC; Whatley MA; Bryant BR; Corcoran EM; Kurdziel KA; Pittaluga S; Paik CH; Lee JH; Fleisher TA; Carrasquillo JA; Waldmann TA
    Cancer Biother Radiopharm; 2020 May; 35(4):249-261. PubMed ID: 32275165
    [No Abstract]   [Full Text] [Related]  

  • 18. Long-Term Results with Thiotepa-Containing Conditioning Regimens for Autologous Stem Cell Transplantation.
    Cohen YI; Lebel E; Zimran E; Shaulov A; Stepensky P; Grisariu S; Avni B
    Transplant Cell Ther; 2023 Aug; 29(8):505.e1-505.e8. PubMed ID: 37160229
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of Implementing a Bendamustine-Based Conditioning Regimen on Outcomes of Autologous Stem Cell Transplantation in Lymphoma while Novel Cellular Therapies Emerge.
    Lachance S; Bourguignon A; Boisjoly JA; Bouchard P; Ahmad I; Bambace N; Bernard L; Cohen S; Delisle JS; Fleury I; Kiss T; Mollica L; Roy DC; Sauvageau G; Veilleux O; Zehr J; Chagnon M; Roy J
    Transplant Cell Ther; 2023 Jan; 29(1):34.e1-34.e7. PubMed ID: 36243319
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Carmustine, etoposide, cytarabine and melphalan versus a newly designed intravenous busulfan-based Busulfex, etoposide and melphalan conditioning regimen for autologous hematopoietic cell transplant: a retrospective matched-pair analysis in advanced Hodgkin and non-Hodgkin lymphomas.
    Sakellari I; Mallouri D; Batsis I; Apostolou C; Konstantinou V; Abela EM; Douka V; Marvaki A; Karypidis K; Iskas M; Baliakas P; Kaloyannidis P; Yannaki E; Sotiropoulos D; Kouvatseas G; Smias C; Anagnostopoulos A
    Leuk Lymphoma; 2015; 56(11):3071-81. PubMed ID: 25760637
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.